Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
3
×
national top stories
san francisco blog main
san francisco top stories
amgen
biotech
deals
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco
adeno-associated virus
alex azar
alexandria venture investments
alliance for aging research
altitude life science ventures
american society of gene and cell therapy
arch venture partners
biogen
biotechnology innovation organization
boulder/denver blog main
boulder/denver top stories
boxer capital
cancer
cancer drugs
clinical trials
cobimetinib
detroit blog main
detroit top stories
dravet syndrome
drug pricing
duane schulthess
ed kaye
eli lilly
encoded therapeutics
erica whittaker
What
despite
3
×
drug
administration
angry
anti
benefited
cancer
crude
cutting
edge
effects
encoded
family
fear
gene
hardest
help
hit
hottest
hunters
illumina’s
industry
ipo
lasting
limited
limits
long
losing
medicine
medicines
nabs
pharma
plans
presidential
price
progress
promising
proteins
push
ras
Language
unset
Current search:
despite
×
" national blog main "
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans